Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice

• Published in: Neurotoxicology and teratology 2016-11, Vol.58, p.15-22
• Main Authors: Gilbert, Marcoita T, Sulik, Kathleen K, Fish, Eric W, Baker, Lorinda K, Dehart, Deborah B, Parnell, Scott E
• Format: Article
• Language: English
• Subjects: Abnormalities, Drug-Induced - embryology; Animals; Brain - drug effects; Brain - embryology; Brain - pathology; C57BL/6J mice; CP-55,940; Cyclohexanols - administration & dosage; Cyclohexanols - toxicity; Dose-Response Relationship, Drug; Emergency; Female; Male; Medical Education; Mice; Mice, Inbred C57BL; Neurulation; Neurulation - drug effects; Pregnancy; Prenatal Exposure Delayed Effects - pathology; Receptor, Cannabinoid, CB1 - metabolism; Synthetic cannabinoid; Teratogen; Teratogens
• ISSN: 0892-0362; 1872-9738
• DOI: 10.1016/j.ntt.2015.12.004

Abstract Potent synthetic cannabinoids (SCBs) are illegally distributed drugs of abuse that are frequently consumed in spite of their adverse consequences. This study was designed to determine if the toxicity observed in adults also extends to the prenatal period by examining the developmental toxicity/teratogenicity of one of these SCBs, CP-55,940, in a mammalian model. First, immunohistochemistry was employed for cannabinoid receptor 1 (CB1) localization within gestational day (GD) 8 mouse embryos; this receptor was identified in the cranial neural plate, suggesting that the endogenous cannabinoid system may be involved in normal development. Based on this information and on previous avian teratogenicity studies, the current investigation focused on cannabinoid exposure during neurulation. The treatment paradigm involved acute i.p. administration of vehicle, 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/kg CP-55,940 to time-mated C57Bl/6J mice on their 8th day of pregnancy (n > 10 litters per treatment group). On GD 17, litters were harvested and examined for numbers of live, dead, or resorbed fetuses, as well as for fetal weight, length, and gross morphological abnormalities. No effect on litter size, fetal weight, or crown rump length was seen at any of the CP-55,940 dosages tested. Major malformations involving the craniofacies and/or eyes were noted in all drug-treated groups. Selected fetuses with craniofacial malformations were histologically sectioned and stained, allowing investigation of brain anomalies. Observed craniofacial, ocular, and brain abnormalities in drug-treated fetuses included lateral and median facial clefts, cleft palate, microphthalmia, iridial coloboma, anophthalmia, exencephaly, holoprosencephaly, and cortical dysplasia. With the most commonly observed defects involving the eyes, the incidence and severity of readily identifiable ocular malformations were utilized as a basis for dose–response analyses. Ocular malformation ratings revealed dose-dependent CP-55,940 teratogenicity within the full range of dosages tested. While examination of additional critical periods and in depth mechanistic studies is warranted, the results of this investigation clearly show the dose-dependent teratogenicity of this SCB.